Comment
|
GSK3 is a component of the destruction complex which is best known as a regulator of beta-catenin levels and is disrupted by activation of the canonical Wnt pathway. Previous work indicates that this pool of GSK3 regulates mTOR, by maintaining high activity of the mTOR suppressor TSC2 (which also is a component of the destruction complex). (cited information)
|
Formal Description Interaction-ID: 44928
|
|
Drugbank entries
|
Show/Hide entries for
GSK3B
|
Drugbank
DB01356
|
|
Drugbank
DB01772
|
3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl] ...
|
Drugbank
DB01793
|
|
Drugbank
DB01950
|
N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thia ...
|
Drugbank
DB02010
|
|
Drugbank
DB02052
|
|
Drugbank
DB03431
|
|
Drugbank
DB03444
|
(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h) ...
|
Drugbank
DB04014
|
|
Drugbank
DB04395
|
Phosphoaminophosphonic Acid-Adenylate Es ...
|
Drugbank
DB07014
|
2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4- ...
|
Drugbank
DB07058
|
5-[1-(4-methoxyphenyl)-1H-benzimidazol-6 ...
|
Drugbank
DB07149
|
(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluo ...
|
Drugbank
DB07584
|
N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phe ...
|
Drugbank
DB07585
|
5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4 ...
|
Drugbank
DB07676
|
3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)- ...
|
Drugbank
DB07812
|
N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyr ...
|
Drugbank
DB07859
|
4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL ...
|
Drugbank
DB07947
|
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CH ...
|
Drugbank
DB08073
|
(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1 ...
|
Drugbank
DB01772
|
3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl] ...
|
Drugbank
DB01793
|
|
Drugbank
DB01950
|
N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thia ...
|
Drugbank
DB02010
|
|
Drugbank
DB02052
|
|
Drugbank
DB03431
|
|
Drugbank
DB04014
|
|
Drugbank
DB04395
|
Phosphoaminophosphonic Acid-Adenylate Es ...
|
|
|